NA
NAGE.US Niagen Bioscience, Inc.
- Market cap
- USD 164M
- P/E
- 17.2x
- P/B
- 1.96x
- ROE
- 9.8%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is NAGE.US undervalued?
Graham numberNAGE.US trades 22.6% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Niagen Bioscience, Inc. fundamental analysis
No fundamental analysis for Niagen Bioscience, Inc. yet.
Niagen Bioscience, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingred…
Full company profileNiagen Bioscience, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Niagen Bioscience, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 21.7M | 21.2M | 31.6M | 46.3M | 59.3M | 67.4M | 72.1M | 83.6M | 99.6M | 129M | 118M |
| Gross Profit | 10.4M | 10.5M | 16.1M | 25.8M | 35.3M | 41.5M | 42.8M | 50.8M | 61.6M | 83.2M | 75.2M |
| Operating Income | -2.91M | -16.4M | -33.2M | -31.3M | -19.9M | -27.1M | -18.6M | -5.60M | 7.73M | 14.3M | 919K |
| EBITDA | -2.49M | -15.7M | -32.3M | -29.8M | -18.3M | -25.4M | -14.7M | -3.23M | 10.3M | 19.6M | 9.67M |
| Net Income | -2.93M | -11.4M | -33.3M | -32.1M | -19.9M | -27.1M | -16.5M | -4.94M | 8.55M | 17.4M | 8.14M |
| EPS | -0.08 | -0.26 | -0.61 | -0.56 | -0.33 | -0.40 | -0.24 | -0.07 | 0.11 | 0.20 | 0.10 |
| Balance Sheet | |||||||||||
| Total Assets | 19.8M | 62.7M | 42.2M | 40.2M | 38.4M | 57.8M | 54.1M | 55.0M | 68.3M | 106M | 109M |
| Total Liabilities | 9.78M | 8.89M | 15.1M | 19.8M | 21.9M | 26.1M | 25.4M | 26.5M | 22.2M | 29.9M | 25.6M |
| Shareholders' Equity | 9.97M | 53.8M | 27.2M | 20.4M | 16.4M | 31.7M | 28.7M | 28.5M | 46.1M | 76.5M | 83.1M |
| Cash & Short-term Investments | 1.64M | 45.4M | 22.4M | 18.6M | 16.5M | 28.0M | 20.3M | 27.2M | 44.5M | 64.8M | 69.5M |
| Total Debt | 599K | 506K | 310K | 1.72M | 1.64M | 4.70M | 4.26M | 3.28M | 2.65M | 2.82M | 2.08M |
| Cash Flow | |||||||||||
| Operating Cash Flow | -2.94M | -9.80M | -20.9M | -20.4M | -10.6M | -24.2M | -15.1M | 7.12M | 12.1M | 13.4M | 5.60M |
| Capital Expenditure | 1.72M | 1.35M | 1.45M | 753K | 142K | 409K | 334K | 148K | 163K | 292K | 269K |
| Free Cash Flow | -4.66M | -11.2M | -22.4M | -21.2M | -10.7M | -24.6M | -15.4M | 6.97M | 11.9M | 13.1M | 5.33M |
| Ratios | |||||||||||
| ROE | -29.4% | -21.1% | -122.6% | -157.2% | -121.3% | -85.5% | -57.7% | -17.4% | 18.5% | 22.7% | 9.8% |
| ROA | -14.8% | -18.1% | -78.9% | -79.9% | -51.9% | -46.9% | -30.6% | -9.0% | 12.5% | 16.3% | 7.5% |
| Net Profit Margin | -13.5% | -53.7% | -105.6% | -69.4% | -33.6% | -40.2% | -23.0% | -5.9% | 8.6% | 13.4% | 6.9% |
| Debt to Equity | 0.06x | 0.01x | 0.01x | 0.08x | 0.10x | 0.15x | 0.15x | 0.12x | 0.06x | 0.04x | 0.03x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Niagen Bioscience, Inc. dividends
Niagen Bioscience, Inc. has not paid dividends in the last 9 fiscal years.
Last stock split: 1:3 on Apr 13, 2016.
Who owns Niagen Bioscience, Inc.
- Insiders 30.90%
- Institutions 38.53%
- Public & others 30.57%
- Shares outstanding 79.2M
- Free float 59.1M
Top funds holding NAGE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 1.47M | 1.86% | 0.00% | Sep 2026 |
| iShares Russell 2000 ETF | 1.46M | 1.84% | 0.00% | Oct 2026 |
| Fidelity Small Cap Index | 626K | 0.79% | 0.00% | Aug 2026 |
| Vanguard Consumer Staples ETF | 588K | 0.74% | -1.11% | Sep 2026 |
| iShares Russell 2000 Growth ETF | 550K | 0.69% | -0.38% | Oct 2026 |
| Vanguard Russell 2000 ETF | 338K | 0.43% | +2.04% | Sep 2026 |
| Schwab US Small-Cap ETF™ | 303K | 0.38% | +0.23% | Oct 2026 |
| VictoryShares Small Cap Fr CA Flw ETF | 285K | 0.36% | +0.31% | Oct 2026 |
| Fidelity Extended Market Index | 283K | 0.36% | -0.38% | Sep 2026 |
| Victory Small Cap Stock | 283K | 0.36% | 0.00% | Sep 2026 |
| iShares Micro-Cap ETF | 174K | 0.22% | 0.00% | Oct 2026 |
| Vanguard Explorer Inv | 169K | 0.21% | 0.00% | Sep 2026 |
| Bridge Builder Small Cap Fund | 158K | 0.20% | 0.00% | Oct 2026 |
| Gabelli Equity Trust | 151K | 0.19% | +4.86% | Jun 2026 |
| Schwab Small Cap Index | 141K | 0.18% | 0.00% | Sep 2026 |
| Amplify Etho Climate Leadership U.S. ETF | 132K | 0.17% | 0.00% | Oct 2026 |
| PV BUYBACK USA Classe B USD | 130K | 0.16% | 0.00% | Jun 2026 |
| iShares Russell 2000 Small-Cap Idx Instl | 106K | 0.13% | -14.92% | Sep 2026 |
| Fidelity Total Market Index | 103K | 0.13% | -0.05% | Sep 2026 |
| Goldman Sachs ActiveBeta® US SmCp Eq ETF | 102K | 0.13% | 0.00% | Oct 2026 |
Top institutions holding NAGE.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| BlackRock Inc | 4.18M | 5.28% | +8.09% | Jun 2026 |
| Steel Peak Wealth Management LLC | 3.50M | 4.42% | +3.77% | Jun 2026 |
| Tieton Capital Management, LLC | 2.47M | 3.12% | +22.93% | Sep 2026 |
| Vanguard Capital Management, LLC | 2.15M | 2.71% | -0.11% | Jun 2026 |
| Qube Research & Technologies | 1.63M | 2.05% | -5.23% | Jun 2026 |
| Geode Capital Management, LLC | 1.48M | 1.87% | +9.94% | Jun 2026 |
| UBS Group AG | 1.28M | 1.62% | -8.70% | Jun 2026 |
| The Goldman Sachs Group Inc | 1.26M | 1.59% | +0.86% | Jun 2026 |
| Arrowstreet Capital Limited Partnership | 1.17M | 1.48% | -50.76% | Jun 2026 |
| Vanguard Portfolio Management, LLC | 1.17M | 1.47% | -4.52% | Jun 2026 |
| State Street Corp | 1.08M | 1.37% | -0.17% | Jun 2026 |
| Citadel Advisors Llc | 630K | 0.80% | +18.78% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 505K | 0.64% | +32.46% | Jun 2026 |
| Victory Capital Management Inc. | 473K | 0.60% | +11.27% | Jun 2026 |
| AQR Capital Management LLC | 472K | 0.60% | -54.23% | Jun 2026 |
| SEI Investments Co | 472K | 0.60% | -51.43% | Jun 2026 |
| Northern Trust Corp | 467K | 0.59% | +17.84% | Jun 2026 |
| Connor Clark & Lunn Inv Mgmt Ltd | 459K | 0.58% | -21.26% | Jun 2026 |
| Charles Schwab Investment Management Inc | 432K | 0.55% | -3.52% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 400K | 0.51% | +6.92% | Jun 2026 |
Niagen Bioscience, Inc. company profile
- Company name
- Niagen Bioscience, Inc.
- Ticker
- NAGE.US
- Exchange
- USA Stocks
- Listed since
- Jul 15, 2008
- Sector
- Consumer Defensive
- Industry
- Life Sciences Tools & Services
- Employees
- 117
- Fiscal year end
- December
- Address
- 10900 Wilshire Blvd, Los Angeles, CA, United States, 90024
- Phone
- 310 388 6706
- Website
- niagenbioscience.com
About Niagen Bioscience, Inc.
Niagen Bioscience, Inc. operates as a bioscience company engages in developing healthy aging products. The company operates through Consumer products; Ingredients; and Pharmaceutical Segments. It provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; nicotinamide adenine dinucleotide (NAD+), an essential coenzyme that regulates cellular metabolism; and develops and commercializes proprietary-based ingredient technologies, including food-grade, Niagen, and pharmaceutical-grade Niagen and supplies these ingredients as raw materials to the manufacturers of consumer products. In addition, it commercializes NAD+ precursor nicotinamide riboside as the flagship ingredient under NIAGEN brand name. The company distributes TRU NIAGEN products direct to consumers through its propriety e-commerce platform TRUNIAGEN.com, Amazon, and other internet marketplaces, as well as specialty retailers and authorized healthcare practitioners resellers. The company was formerly known as ChromaDex Corporation and changed its name to Niagen Bioscience, Inc. in March 2025. Niagen Bioscience, Inc. was founded in 1999 and is headquartered in Los Angeles, California.
Niagen Bioscience, Inc. management
10- Mr. Frank Louis Jaksch Jr.Co-Founder & Chairman · born 1968
- Mr. Robert N. FriedCEO & Director · born 1960
- Mr. Ozan Pamir C.F.A.CFO & Principal Accounting Officer · born 1992
- Mr. Carlos LopezSenior VP & General Counsel · born 1981
- Dr. Andrew Shao Ph.D.Senior Vice President of Global Regulatory & Scientific Affairs
- Ms. Michiko KelleyChief Marketing Officer
- Ms. Chu YanManaging Director of Asia Pacific
- Kendall KnyschHead of Media Relations & Partnerships
- Mr. James LeeController · born 1976
- Wesley YuVice President of Finance